Rallybio Targets Nov. 20 Merger Close, Updates $13.90 Cash Distribution

Rallybio expects to complete its merger after November 20, 2026, and distribute $13.90 per share in cash to eligible stockholders and warrant holders on November 30, according to a regulatory filing. The distribution is subject to Nasdaq due bill procedures and merger conditions.

Original reporting
Published Nov 12, 2026, 9:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rallybio Targets Nov. 20 Merger Close, Updates $13.90 Cash Distribution — source image
Decision brief

The 30-second read

$RLYBNeutralMed
01

Why it matters

The disclosure provides a clear timeline for investors, creating a short‑term trading opportunity around the distribution.

02

Market read

The announcement is a primary corporate action that may drive short‑term price movement.

03

What to watch

Potential tax implications of the cash distribution for pre-funded warrant holders.

Relevance 7/10Novelty 7/10Timing: distribution scheduled for Nov 30, merger close on Nov 20

Background

Rallybio filed an 8‑K detailing the expected merger close and cash distribution dates.

Company-level read

Ticker impact

$RLYBNeutralHigh confidence
Context

Rallybio announced its merger will close on Nov 20 and a $13.90 per-share cash distribution to be paid on Nov 30.

Expected impact

likely upward pressure as investors anticipate the cash distribution and merger completion

Evidence & confidence

Cash distributions and merger closings typically generate buying interest; the timing is near-term.

Market effects

The biotech merger may signal continued consolidation activity in the sector.

Limited to U.S. markets where Rallybio trades.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the merger faces unexpected regulatory hurdles, the stock could face downside despite the announced dates.

Key entities

  • Rallybio Corp

    Biotech company completing a merger and issuing a cash distribution.

Related articles

$RLYBHigh

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av